NYSE:LCI - Lannett Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.65 +0.16 (+2.14 %)
(As of 01/21/2019 04:09 AM ET)
Previous Close$7.65
Today's Range$7.40 - $7.74
52-Week Range$3.33 - $24.75
Volume628,674 shs
Average Volume1.49 million shs
Market Capitalization$300.41 million
P/E Ratio2.47
Dividend YieldN/A
Beta1.94
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages. It also provides its products for various medical indications comprising cholesterol, muscle spasm, pain management, irritable bowel, antipsychosis, gastrointestinal, cardiovascular, thyroid deficiency, central nervous system, urinary, migraine, bronchospasms, and gallstone. In addition, the company manufactures active pharmaceutical ingredients. It markets its products under the Lipitor, Lioresal, Bentyl, Prolixin, MiraLAX, Imdur, Levoxyl/Synthroid, Concerta, Toprol-XL, Prilosec, Ditropan, Protonix, Imitrex, Brethine, and Actigall brands to generic pharmaceutical and private label distributors, drug wholesalers, chain drug retailers, mail-order pharmacies, other pharmaceutical manufacturers, managed care and health maintenance organizations, hospital buying groups, and governmental entities. The company has supply and development agreements with Jerome Stevens Pharmaceuticals, Summit Bioscience LLC, HEC Pharm Group, Andor Pharmaceuticals LLC, Dexcel Pharma, and Aralez Pharmaceuticals. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.

Receive LCI News and Ratings via Email

Sign-up to receive the latest news and ratings for LCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP51601210
Phone215-333-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$684.56 million
Cash Flow$4.5536 per share
Book Value$15.76 per share

Profitability

Net Income$28.69 million

Miscellaneous

Employees1,251
Market Cap$300.41 million
OptionableOptionable

Lannett (NYSE:LCI) Frequently Asked Questions

What is Lannett's stock symbol?

Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

How were Lannett's earnings last quarter?

Lannett Company, Inc. (NYSE:LCI) posted its quarterly earnings results on Wednesday, November, 7th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.05. The company earned $155.10 million during the quarter, compared to analyst estimates of $145.79 million. Lannett had a negative net margin of 39.74% and a positive return on equity of 21.32%. Lannett's revenue for the quarter was up .1% compared to the same quarter last year. During the same period last year, the firm posted $0.60 EPS. View Lannett's Earnings History.

When is Lannett's next earnings date?

Lannett is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Lannett.

What price target have analysts set for LCI?

6 Wall Street analysts have issued 12-month price objectives for Lannett's shares. Their forecasts range from $8.00 to $43.00. On average, they anticipate Lannett's stock price to reach $24.8750 in the next year. This suggests a possible upside of 225.2% from the stock's current price. View Analyst Price Targets for Lannett.

What is the consensus analysts' recommendation for Lannett?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lannett in the last year. There are currently 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lannett.

Has Lannett been receiving favorable news coverage?

News articles about LCI stock have trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Lannett earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of Lannett's key competitors?

Who are Lannett's key executives?

Lannett's management team includes the folowing people:
  • Mr. Timothy C. Crew, CEO & Director (Age 57)
  • Mr. Martin P. Galvan, VP of Fin. & CFO (Age 66)
  • Mr. Samuel H. Israel, Gen. Counsel & Chief Legal Officer (Age 56)
  • Mr. John M. Abt, VP & Chief Quality Operations Officer (Age 53)
  • Mr. John Kozlowski, Chief of Staff & Strategy Officer (Age 46)

Who are Lannett's major shareholders?

Lannett's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Louisiana State Employees Retirement System (0.03%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Lannett stock include Albert Paonessa III, Arthur P Bedrosian, David Farber, Kevin Smith, Patrick G Lepore and Timothy C Crew. View Institutional Ownership Trends for Lannett.

Which major investors are selling Lannett stock?

LCI stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. View Insider Buying and Selling for Lannett.

Which major investors are buying Lannett stock?

LCI stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Lannett stock in the last two years include Albert Paonessa III, Arthur P Bedrosian, Patrick G Lepore and Timothy C Crew. View Insider Buying and Selling for Lannett.

How do I buy shares of Lannett?

Shares of LCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lannett's stock price today?

One share of LCI stock can currently be purchased for approximately $7.65.

How big of a company is Lannett?

Lannett has a market capitalization of $300.41 million and generates $684.56 million in revenue each year. The company earns $28.69 million in net income (profit) each year or $3.10 on an earnings per share basis. Lannett employs 1,251 workers across the globe.

What is Lannett's official website?

The official website for Lannett is http://www.lannett.com.

How can I contact Lannett?

Lannett's mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company can be reached via phone at 215-333-9000.


MarketBeat Community Rating for Lannett (NYSE LCI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  401 (Vote Outperform)
Underperform Votes:  318 (Vote Underperform)
Total Votes:  719
MarketBeat's community ratings are surveys of what our community members think about Lannett and other stocks. Vote "Outperform" if you believe LCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel